EPISODE · May 5, 2022 · 5 MIN
Thursday, May 5, 2022
from The Gist Healthcare Podcast
The FDA says there’s "no evidence" that doubling an individual’s dose of Paxlovid will reduce the return of COVID symptoms. Mental health telemedicine company Cerebral stops prescribing Adderall to new patients as the company faces increasing scrutiny for its marketing and prescribing practices. And a Health Affairs study finds several physicians in insurers’ Medicaid networks aren’t seeing patients. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
The FDA says there’s "no evidence" that doubling an individual’s dose of Paxlovid will reduce the return of COVID symptoms. Mental health telemedicine company Cerebral stops prescribing Adderall to new patients as the company faces increasing scrutiny for its marketing and prescribing practices. And a Health Affairs study finds several physicians in insurers’ Medicaid networks aren’t seeing patients. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Thursday, May 5, 2022
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m